Researchers report that regular caffeinated coffee was associated with a lower rate of atrial fibrillation recurrence in a six month randomized trial of older adults. The Does Eliminating Coffee Avoid Fibrillation, or Decaf, trial enrolled 200 patients with persistent irregular heartbeats and compared those instructed to continue at least one cup a day with participants who were asked to abstain. Recurrence occurred in 47 percent of the coffee group versus 64 percent of the abstention group, a 17 percentage point difference during follow up. The findings were published in the Journal of the American Medical Association and presented at the American Heart Association annual meeting in New Orleans.
Key takeaways
- The Decaf randomized clinical trial included 200 older adults with persistent atrial fibrillation and ran for six months.
- Participants were randomized to either continue drinking at least one cup of caffeinated coffee daily or to abstain from caffeine.
- Arrhythmia recurrence was 47 percent for the coffee group and 64 percent for the abstain group, a 17 percentage point absolute difference.
- The trial used clinic electrocardiograms and wearable monitors to detect episodes and relied on intermittent video visits for selfreported intake verification.
- The study population came from the United States, Canada and Australia and included people who had regularly consumed coffee within the prior five years.
- Authors note important limitations: caffeine from other beverages was not fully isolated and the study did not track changes in exercise or diet.
- Findings were published in JAMA and were presented publicly at the American Heart Association conference, increasing visibility within cardiology circles.
Background
Atrial fibrillation, commonly called A fib, affects more than 10 million people in the United States and raises risks of heart failure, blood clots and stroke. Conventional clinical advice has often urged patients with A fib to limit or avoid caffeinated beverages because caffeine can raise heart rate and provoke palpitations in some individuals. Observational studies of coffee and arrhythmia risk have been inconsistent, in part because habitual intake, tolerance and other lifestyle factors are hard to disentangle from health outcomes. That uncertainty set the stage for a randomized trial to evaluate whether continuing caffeinated coffee changes short term recurrence risk among people already diagnosed with persistent A fib.
The Decaf trial was designed as a pragmatic study, enrolling older adults who had consumed coffee at some point in the previous five years rather than recruiting only caffeinenaive volunteers. That approach aimed to test a realistic clinical question: does stopping regular coffee reduce arrhythmia recurrence. Trialists used a combination of self reports, clinic electrocardiograms and wearable rhythm monitors to identify episodes, recognizing that continuous monitoring for every participant was not feasible. The randomized design gives stronger causal leverage than prior observational work, but the trial size and follow up duration impose limits on how broadly the results can be generalized.
Main event
The trial randomized 200 participants to two arms: caffeine abstention or continued caffeinated coffee consumption, with study staff monitoring adherence through video checkups and self reports. Investigators recorded arrhythmia events using electrocardiograms collected at clinic visits and wearable monitors worn by participants at prespecified intervals. Over six months, 47 percent of those instructed to continue coffee experienced at least one recurrence compared with 64 percent in the abstention arm. The difference corresponds to a 17 percentage point absolute reduction and is reported by the authors as a significant change in recurrence risk during the study window.
Gregory Marcus, a cardiologist at the University of California, San Francisco and lead author, framed the finding as evidence that caffeinated coffee may be protective against A fib recurrence in this trial population. The study was submitted for peer review and published in the Journal of the American Medical Association and was also presented at the American Heart Association scientific sessions in New Orleans, giving it broad exposure among clinicians. Participants were geographically diverse across the United States, Canada and Australia, but they were all adults who had drank coffee in the prior five years, which affects how the results apply to lifelong abstainers or younger people.
Investigators and commentators emphasized adherence and measurement challenges. Intake was selfreported during intermittent telehealth contacts, and the protocol did not fully control for other caffeine sources such as tea or energy drinks. The trial also did not collect detailed, standardized data on participants lifestyle changes such as exercise or dietary adjustments that could influence arrhythmia risk. Those design choices were intentional to preserve a pragmatic, realworld setting but they mean residual confounding cannot be entirely excluded.
Analysis and implications
The randomized design strengthens confidence that continued caffeinated coffee was associated with lower short term recurrence of atrial fibrillation in this specific cohort, but causality beyond the trial conditions remains a cautious inference. The 17 percentage point difference is clinically meaningful for patients worried about recurrent A fib episodes over months, yet longer follow up would be needed to know if the benefit endures or if other harms emerge. Clinicians who previously advised universal caffeine avoidance for A fib patients may reconsider a more individualized approach that permits moderate coffee for many patients.
Biologic mechanisms that could explain a protective association are not definitively established. Some experimental work suggests caffeine metabolites can influence autonomic tone, inflammation and atrial electrophysiology in ways that might reduce arrhythmia propensity in habitual consumers. At the same time, caffeine is a stimulant and can increase heart rate in some people, so individual responses will vary and a net protective effect in a randomized trial does not guarantee benefit for every patient.
From a public health standpoint, the trial does not support a new universal prescription to drink coffee for cardiac protection because it was limited to older adults with prior coffee exposure and had a short follow up. However, it does provide evidence to inform shared decision making: many patients with A fib who enjoy moderate caffeinated coffee may not need to stop, and clinicians can weigh the trial findings alongside comorbidities, medication interactions and patient preferences.
Comparison and data
| Group | Recurrence rate at 6 months |
|---|---|
| Caffeinated coffee arm | 47 percent |
| Caffeine abstention arm | 64 percent |
The table summarizes the primary numerical outcome reported by the trialists. The 17 percentage point absolute difference translates to a relative risk reduction of approximately 26.6 percent when comparing 47 percent versus 64 percent, but absolute differences best communicate patient level impact. The trial was not powered to evaluate rare adverse events or to detect modest subgroup differences across age, sex or comorbidity strata.
Reactions and quotes
Marcus described the result as showing how protective caffeinated coffee does seem to be to prevent atrial fibrillation in the trial population.
Gregory Marcus, cardiologist, University of California San Francisco
Mount Sinai cardiologist Johanna Contreras said the study suggests it is acceptable for people with A fib to have a cup of coffee in the morning but stopped short of calling coffee definitively protective.
Johanna Contreras, cardiologist, Mount Sinai Fuster Heart Hospital
Unconfirmed
- Whether caffeine from tea, soft drinks or energy drinks materially contributed to the observed effect is not confirmed because other caffeine sources were not fully isolated.
- Long term benefits beyond the six month trial period remain unproven and require longer follow up.
- Generalizability to younger patients, lifelong coffee abstainers or populations with different comorbidity profiles is uncertain.
Bottom line
The Decaf randomized trial adds credible evidence that continuing moderate caffeinated coffee was associated with a lower short term recurrence of atrial fibrillation in a cohort of 200 older adults who had previously consumed coffee. The magnitude of the difference, 47 percent versus 64 percent recurrence over six months, is meaningful for patients and clinicians making near term management decisions. Nevertheless, the pragmatic design, limited sample size and six month follow up mean clinicians should interpret the results in context, accounting for individual tolerance to caffeine, medication interactions and stroke prevention needs.
For most patients with A fib who enjoy moderate coffee, the trial supports a permissive stance rather than automatic abstention, while those who experience clear caffeine triggered palpitations should continue to avoid it. Further research with larger, more diverse populations and longer follow up will be needed before coffee could be recommended as a preventive strategy for atrial fibrillation recurrence.
Sources
- The Guardian — news report summarizing the study and reactions
- Journal of the American Medical Association — peer reviewed publication (study published in JAMA)
- American Heart Association — conference presentation at AHA scientific sessions, New Orleans (official conference)
- NBC News — media interview coverage with lead investigator and external expert